Zykadia (ceritinib) is a small molecule pharmaceutical. Ceritinib was first approved as Zykadia on 2014-04-29. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target testis-specific serine/threonine-protein kinase 1, insulin receptor, insulin-like growth factor 1 receptor, and receptor-type tyrosine-protein kinase FLT3. Zykadia's patents are valid until 2032-02-02 (FDA).
|Indication||non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors|